CXCL12 and central nervous system cancer: This trial aimed to evaluate the efficacy of Plerixafor in treating patients with newly diagnosed high-grade glioma, leveraging its ability to disrupt TAM recruitment mediated by the SDF-1/CXCL12 axis.